• Barbui, T., Barosi, G., Grossi, A., Gugliotta, L., Liberato, L.N., Marchetti, M., Mazzucconi, M.G., Rodeghiero, F. & Tura, S. (2004) Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 89, 215232.
  • Barbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., Rodeghiero, F., D’Amore, E., Randi, M.L., Bertozzi, I., Marino, F., Vannucchi, A.M., Antonioli, E., Carrai, V., Gisslinger, H., Buxhofer-Ausch, V., Müllauer, L., Carobbio, A., Gianatti, A., Gangat, N., Hanson, C.A. & Tefferi, A. (2010) Survival and risk of leukemic transformation in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study on 1104 patients. Blood (ASH Annual Meeting Abstracts), 116, 457.
  • Falanga, A., Marchetti, M., Barbui, T. & Smith, C.W. (2005) Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Seminars in Hematology, 42, 239247.
  • Griesshammer, M. (2006) Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Seminars in Thrombosis and Hemostasis, 32, 372380.
  • Michiels, J.J., Berneman, Z., Schroyens, W., Finazzi, G., Budde, U. & van Vliet, H.H. (2006) The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Seminars in Thrombosis and Hemostasis, 32, 589604.
  • Murphy, S., Peterson, P., Iland, H. & Laszlo, J. (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Seminars in Hematology, 34, 2939.
  • Palandri, F., Catani, L., Testoni, N., Ottaviani, E., Polverelli, N., Fiacchini, M., De Vivo, A., Salmi, F., Lucchesi, A., Baccarani, M. & Vianelli, N. (2009) Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. American Journal of Hematology, 84, 215220.
  • Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G., Marchioli, R., Marfisi, R.M., Finazzi, G., Guerini, V., Fabris, F., Randi, M.L., De Stefano, V., Caberlon, S., Tafuri, A., Ruggeri, M., Specchia, G., Liso, V., Rossi, E., Pogliani, E., Gugliotta, L., Bosi, A. & Barbui, T. (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, 110, 840846.
  • Vardiman, J.W., Harris, N.L. & Brunning, R.D. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100, 22922302.
  • Wolanskyj, A.P., Lasho, T.L., Schwager, S.M., McClure, R.F., Wadleigh, M., Lee, S.J., Gilliland, D.G. & Tefferi, A. (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. British Journal of Haematology, 131, 208213.